Conditions Encyclopedia: 16 FDA-Approved + 30 Off-Label Indications

Scope: Comprehensive condition-by-condition reference covering all 16 FDA-approved (UHMS) indications and 30 off-label applications. Each monograph addresses pathophysiology, mechanism of HBOT action, protocol specifics, clinical outcomes, and evidence quality.

PART I: FDA-APPROVED (UHMS-APPROVED) INDICATIONS

1. Air or Gas Embolism

What it is: Air or gas embolism occurs when gas bubbles enter the arterial or venous circulation, obstructing blood flow and causing ischemia to downstream tissues. Arterial gas embolism (AGE) — the more dangerous form — most commonly results from pulmonary barotrauma during ascent in scuba diving, iatrogenic causes (central line placement, cardiac surgery, endoscopy, laparoscopy), or trauma. Venous air embolism (VAE) can result from neurosurgery in the sitting position, cesarean section, or any procedure where a venous entry point is exposed to atmospheric or subatmospheric pressure. Bubbles entering the cerebral or coronary circulation cause immediate ischemia that mimics stroke or myocardial infarction.

Why HBOT works: HBOT exploits two physical laws. By Boyle's Law, increasing ambient pressure directly compresses the gas bubble, reducing its volume and restoring perfusion. By Henry's Law, raising blood oxygen partial pressure (~2000 mmHg at 3 ATA) creates a steep gradient that drives nitrogen out of the bubble into plasma for subsequent exhalation, accelerating bubble reabsorption. Beyond mechanical bubble shrinkage, HBOT reduces cerebral edema via vasoconstriction while simultaneously delivering supraphysiologic oxygen to ischemic tissue, inhibiting neutrophil-endothelial adhesion and blunting reperfusion injury.

Protocol: US Navy Treatment Table 6A is used for serious gas embolism: initial compression to 165 fsw (6 ATA breathing air) if monoplace chambers are unavailable, or more commonly 2.8 ATA (60 fsw) breathing 100% oxygen via Table 6 for ~4 hours 45 minutes. Treatment should begin within 6 hours of symptom onset for best outcomes; however, case reports document meaningful neurological recovery even with delayed treatment. Repeat sessions at 2–2.8 ATA may be needed for residual deficits.

Outcomes: Early HBOT within 6 hours is associated with excellent neurological recovery in cerebral air embolism cases. One published case series found ~90% of patients with AGE treated promptly with HBOT recovered fully or near-fully. Even delayed initiation (>6 hours) has yielded neurological recovery in published reports. The intervention is considered standard of care with no ethical equipoise for a sham-controlled RCT.

Evidence quality: Level C (expert consensus, case series, physiologic rationale); no RCTs exist or are considered ethical given the life-threatening nature of the condition.

Key citations: Vann et al., PMC7470655 (vascular air embolism, HBOT mechanisms); PMC6820324 (cerebral air embolism case, USN Table 6).

2. Carbon Monoxide Poisoning (Including Cyanide Complications)

What it is: Carbon monoxide (CO) poisoning is the most common cause of poisoning death in the developed world. CO binds hemoglobin with ~250× the affinity of oxygen, forming carboxyhemoglobin (COHb) and rendering blood incapable of oxygen delivery. Simultaneously, CO binds cytochrome c oxidase, impairing mitochondrial respiration. Neurological sequelae — including cognitive impairment, personality change, and parkinsonism — can appear days to weeks after apparent recovery ("delayed neurological syndrome," DNS). Fire-related exposures frequently involve concomitant cyanide inhalation from burning synthetic materials, compounding mitochondrial toxicity.

Why HBOT works: 100% oxygen at 3 ATA reduces COHb half-life from ~320 minutes (room air) to approximately 23 minutes. Critically, elevated dissolved oxygen bypasses hemoglobin entirely, directly correcting cytochrome c oxidase dysfunction. HBOT also reduces lipid peroxidation in the brain and inhibits the delayed neutrophil-mediated oxidative injury mechanism implicated in DNS.

Protocol: The landmark Weaver 2002 RCT used three HBOT sessions: session 1 at 3.0 ATA × 60 minutes + 2.0 ATA × 60 minutes; sessions 2 and 3 at 2.0 ATA × 120 minutes each, given at 6–12 hour intervals. Many centers use a simplified 2.5–3.0 ATA × 90 minutes protocol. UHMS consensus recommends HBOT for patients with: loss of consciousness, neurological deficits, cardiac ischemia, COHb >25%, or pregnancy at any COHb level. Initiation within 6 hours is strongly preferred.

Outcomes: Weaver et al. (NEJM 2002) demonstrated a significant reduction in cognitive sequelae at 6 weeks (46.1% vs 25.6% in the HBOT group, p=0.007). Retrospective database studies of >25,000 cases have shown HBOT associated with reduced 4-year mortality (Huang et al.) and reduced neurocognitive sequelae (Nakajima et al. 2020). Two European RCTs (Raphael 1989, Annane 2011) showed no benefit, but were conducted at 2.0 ATA — below the mechanistically supported 2.5–3.0 ATA threshold — and had methodological limitations.

Evidence quality: Class IIa, Level A (UHMS). The Weaver trial remains the highest-quality RCT. Evidence favors HBOT at ≥2.5 ATA for moderate-to-severe poisoning.

Key citations: Weaver et al., NEJM 2002; PMC11651343 (review supporting ≥2.5 ATA); PMC7066484 (Cochrane update); PMC6381775.

3. Clostridial Myositis and Myonecrosis (Gas Gangrene)

What it is: Gas gangrene is a rapidly fatal soft tissue infection caused by Clostridium perfringens (and other Clostridium species). The bacterium produces alpha-toxin, a lecithinase that destroys cell membranes, causing myonecrosis that can spread up to 6 inches per hour. Classic findings include severe pain disproportionate to appearance, crepitus from subcutaneous gas, and systemic toxicity. Untreated mortality approaches 100%; even with surgery and antibiotics, mortality remains 20–30%.

Why HBOT works: C. perfringens is an obligate anaerobe whose growth is inhibited at tissue oxygen tensions above ~70 mmHg, and whose alpha-toxin production ceases at pO₂ >250 mmHg — levels achieved only with HBOT. Additionally, HBOT enhances neutrophil oxidative burst function (which requires O₂ as substrate), promotes antibiotic potency, and demarcates viable from necrotic tissue, allowing more conservative surgical debridement.

Protocol: UHMS recommends 2.8–3.0 ATA × 90 minutes, 2–3 sessions in the first 24 hours, then twice daily for 2–5 additional days. Total: typically 10–20 treatments. Surgical debridement proceeds between HBOT sessions. Antibiotic coverage with penicillin + clindamycin is the preferred adjunct (clindamycin inhibits toxin synthesis at the ribosomal level).

Outcomes: Multiple retrospective studies document a ~50% relative reduction in mortality when HBOT is added to surgery and antibiotics. Studies by Darke, Hart, and others show mortality dropping from approximately 30–40% (surgery + antibiotics alone) to 15–25% (with HBOT). HBOT also reduces the extent of required amputation. A 2015 Cochrane review (PMC8652263) found insufficient RCT data to reach firm conclusions due to ethical constraints on randomization in a potentially fatal disease.

Evidence quality: Level C (case series, historical controls). Ethical constraints preclude RCTs.

Key citations: PMC12111948 (NSTI/gas gangrene HBOT review 2025); NBK500002 (StatPearls protocol); PMC8652263 (Cochrane review).

4. Crush Injury, Compartment Syndrome, and Acute Traumatic Peripheral Ischemia

What it is: Crush injuries — from industrial accidents, natural disasters, or trauma — create a zone of ischemia surrounding directly damaged tissue. Compartment syndrome occurs when swelling within a rigid fascial compartment raises intracompartmental pressure above arteriolar perfusion pressure (~30 mmHg), causing progressive muscle and nerve death despite intact arterial flow. Acute traumatic peripheral ischemia encompasses other mechanisms (arterial disruption, avulsion injuries) that create zones of marginally perfused tissue at risk of infarction.

Why HBOT works: In the "zone of injury" model, HBOT oxygenates ischemic but viable cells at the wound periphery, interrupting the ischemia→edema→further ischemia cycle. Key mechanisms include: (1) vasoconstriction reducing post-capillary edema while maintaining hyperoxic O₂ delivery; (2) inhibition of neutrophil-endothelial adhesion via downregulation of β₂-integrins, reducing reperfusion injury; (3) stimulation of angiogenesis and fibroblast collagen synthesis for healing; (4) enhanced antibiotic efficacy in hypoxic tissue.

Protocol: 2.0–2.5 ATA × 90 minutes, 2–3 times daily initially, then once daily. Total sessions typically 20–40 depending on clinical response. HBOT is adjunctive — fasciotomy for compartment syndrome must not be delayed. HBOT is most valuable after surgical decompression for ongoing tissue preservation.

Outcomes: Human evidence is largely retrospective. A 2025 study of pediatric earthquake victims with crush injuries and compartment syndrome found NPWT and HBOT combined contributed to an 82% limb salvage rate (PMC12782718). Animal studies consistently show reduced muscle necrosis, edema, and loss of function. HBOT after crush injury is associated with reduced myonecrosis and amputation rates in retrospective human series.

Evidence quality: Level C (case series, animal data, retrospective human studies).

Key citations: NBK482232 (StatPearls); PMC12782718 (pediatric crush injury 2025).

5. Decompression Sickness (The Bends)

What it is: Decompression sickness (DCS) occurs when dissolved inert gas (nitrogen in recreational diving, helium in deep commercial diving) comes out of solution as bubbles during or after ascent. "Type I" DCS presents with joint pain ("the bends"), skin mottling, and lymphatic obstruction. "Type II" DCS causes neurological, pulmonary ("the chokes"), or vestibular symptoms from bubbles in the spinal cord, brain, or lung vasculature. DCS is also triggered in aviators (explosive decompression) and tunnel workers. Cerebral arterial gas embolism (CAGE) from pulmonary barotrauma shares its treatment.

Why HBOT works: Recompression directly reduces bubble size (Boyle's Law). Breathing 100% O₂ at 2.8 ATA creates a maximum inert gas gradient driving N₂ from bubbles into blood for elimination via lungs. The oxygen window (inert gas "unsaturation" created by O₂ metabolism) further accelerates N₂ absorption. HBOT also reverses the inflammatory cascade triggered by bubble-endothelial contact and reduces spinal cord edema.

Protocol: US Navy Treatment Table 6 is the gold standard: 2.8 ATA (60 fsw / 18 msw) breathing 100% O₂ with 5-minute air breaks; total duration 4 hours 45 minutes. Table 5 (2 hours 16 minutes) is used for mild pain-only DCS with rapid relief at pressure. Table 7 (up to 36 hours) is reserved for life-threatening cases. Supplemental normobaric 100% O₂ before chamber access accelerates N₂ elimination and reduces required chamber time.

Outcomes: USN Table 6 achieves complete resolution in 73–100% of mild-moderate DCS and 13–63% of severe neurological DCS. Even delayed treatment (>48 hours) yields 76% complete recovery (Hadanny et al., PLOS ONE 2015 — PMC0124919). Early treatment remains superior for severe manifestations. DCS is perhaps the indication with the strongest and oldest evidence base supporting HBOT.

Evidence quality: Level A (historical, mechanistic, and observational data; no RCTs possible given treatment urgency).

Key citations: PMC8426124 (USN TT6 safety); PLOS ONE 2015 (delayed recompression); UHMS DCS chapter.

6. Central Retinal Artery Occlusion (CRAO)

What it is: CRAO is the ophthalmological equivalent of a stroke — sudden occlusion of the central retinal artery causes acute ischemia of the inner retinal layers. Patients present with sudden, painless, profound monocular visual loss. The retina tolerates ischemia poorly; irreversible photoreceptor damage begins within 90–100 minutes (shorter than brain tissue). Most cases are embolic (carotid atherosclerosis, cardiac sources) or thrombotic. Standard treatments (ocular massage, anterior chamber paracentesis, carbogen breathing, IV tPA) have limited evidence.

Why HBOT works: At 2.4–3.0 ATA, dissolved plasma oxygen rises sufficiently to sustain retinal metabolism via diffusion from the choroid (which has a separate blood supply from the retinal artery). This "oxygen bridge" prevents irreversible infarction while waiting for arterial recanalization (which typically begins around 72 hours). HBOT also corrects local acidosis, reduces ROS production, supports ATP synthesis, and may reduce ischemia-reperfusion injury during eventual recanalization.

Protocol: Most centers use 2.4–2.8 ATA × 90 minutes, 2–3 sessions per day for the first 1–3 days, then once daily. A 2026 case series used an initial 3.0 ATA × 50 min + 2.4 ATA × 40 min combined 90-minute protocol, twice daily × 3 days, then once daily for 10 total treatments (PMC12819982). Treatment within 24 hours is critical; some centers extend the window to 48 hours given reports of visual improvement even with delayed initiation.

Outcomes: A 2021 meta-analysis (PMC8370578) of 7 RCTs (251 eyes) found oxygen therapy — predominantly HBOT — improved visual acuity with an odds ratio of 5.61 (95% CI 3.60–8.73) vs. no oxygen treatment. A 2025 retrospective study (PMC12452972) confirmed significantly more patients achieving ≥3 lines of visual improvement with HBOT (p<0.02) and less OCT-documented retinal thinning at 1 month.

Evidence quality: Class IIa, Level A (UHMS, 2011 addition). Strongest evidence for HBOT treatment within 24 hours of onset.

Key citations: PMC8370578 (meta-analysis); PMC12452972 (2025 outcomes study); PMC12819982 (protocol case 2026).

7. Diabetic Foot Ulcers (Wagner Grade III and Above)

What it is: Diabetic foot ulcers affect ~15% of people with diabetes over their lifetime and are the leading cause of non-traumatic lower limb amputation worldwide. The pathophysiology is multifactorial: peripheral neuropathy causes pressure insensitivity; peripheral arterial disease creates ischemia; hyperglycemia impairs neutrophil function, growth factor production, and collagen synthesis. Wagner Grade III ulcers involve deep tissue, abscess, or osteomyelitis; Grade IV involve partial foot gangrene; Grade V involve full-foot gangrene. These represent the high-risk limb-threatening tier.

Why HBOT works: Hypoxia is the core obstacle to healing in diabetic wounds. HBOT (1) acutely corrects wound-edge pO₂ to levels supporting fibroblast proliferation and collagen deposition; (2) potentiates leukocyte oxidative killing of bacteria (O₂-dependent); (3) drives angiogenesis via HIF-1α/VEGF pathways stimulated by cyclic hypoxia-hyperoxia; (4) reduces biofilm formation; and (5) enhances bone vascularization in coexistent osteomyelitis.

Protocol: 2.0–2.5 ATA × 90 minutes, once daily, 5 days/week, for 20–40 sessions total. Standard UHMS course is 30–40 treatments. Patient selection requires: revascularization when indicated, infection control, offloading, and adequate debridement as co-interventions.

Outcomes: A 2024 systematic review and meta-analysis (PMC10962882) of 14 RCTs found HBOT significantly improved healing at ≥8 weeks (RR 2.39, 95% CI 1.87–3.05; p<0.00001), reduced minor amputations (RR 0.58) and major amputations (RR 0.31). A large real-world retrospective study (PMC6338555) of 19,057 Wagner Grade 3/4 ulcers found the healing rate improved from 54% (no HBOT) to 75% (HBOT course completed). The DAMO2CLES RCT (Netherlands, 2023) showed no benefit in a predominantly revascularized population, raising the question of appropriate patient selection.

Evidence quality: Class I, Level A (UHMS). Strong evidence for Wagner III+ in patients with adequate tissue perfusion. Patient selection and treatment adherence are critical determinants of outcome.

Key citations: PMC10962882 (2024 meta-analysis 14 RCTs); PMC6338555 (real-world Wagner III/IV); PMC12809191 (2025 RCT).

8. Severe Anemia (Exceptional Blood Loss)

What it is: This indication applies when acute blood loss has produced critically low hemoglobin levels AND blood transfusion is unavailable or refused (most commonly on religious grounds, as with Jehovah's Witnesses, or due to inability to crossmatch). The hemoglobin may fall below 3–5 g/dL, a level at which normal cellular oxygen demand cannot be met by dissolved plasma oxygen alone under normobaric conditions.

Why HBOT works: At 3.0 ATA breathing 100% O₂, plasma-dissolved oxygen reaches approximately 6.8 mL/dL — sufficient to meet the body's resting oxygen requirement (~5–6 mL/dL) independent of hemoglobin. Boerema's landmark 1959 pig experiments demonstrated this principle: animals exsanguinated to Hgb ~0.4 g/dL survived short-term at 3 ATA on 100% O₂. HBOT thus serves as a "bridge" — acutely correcting oxygen debt while endogenous erythropoiesis recovers over days to weeks, supported by erythropoietin and hematinics.

Protocol: HBOT is delivered in "pulsed" fashion: 2.0–3.0 ATA × 90 minutes (with air breaks) for 3–4 sessions in 24 hours initially. Higher pressures (2.5–3.0 ATA × 3–4 hours) are used for end-organ failure. Surface intervals are titrated to clinical symptoms of hypoxia (altered mental status, tachycardia, metabolic acidosis). HBOT is tapered as hematocrit improves above ~20%. Pulmonary oxygen toxicity limits prolonged high-pressure treatments.

Outcomes: Published human case series document survival in patients who would otherwise have been expected to die from anemia-related organ failure. Clinical endpoints include normalization of heart rate, clearing of metabolic acidosis, and recovery of mental status during treatments. UHMS supports this indication with AHA Class IIa evidence based on animal experiments and human case series (no RCTs exist or are ethical).

Evidence quality: Level C (case series, physiologic rationale, animal experiments). Medicare does not cover this indication; some commercial insurers may.

Key citations: UHMS Indication 7 (severe anemia); woundreference.com protocol; PMC11493705 (Frontiers review 2024); ATSJOURNALS case report.

9. Intracranial Abscess

What it is: Brain abscesses are focal purulent infections within the brain parenchyma, most commonly arising from contiguous sinusitis, otitis media, dental infection, or hematogenous spread. They carry substantial mortality (10–30%) and a high risk of permanent neurological deficit, particularly when abscesses are deep, multiple, or in eloquent brain regions. Standard treatment is prolonged IV antibiotics combined with neurosurgical drainage (aspiration or excision). Residual abscess after standard treatment remains problematic.

Why HBOT works: Abscesses are intrinsically hypoxic environments where many pathogens (anaerobes, streptococci) thrive and neutrophil killing is impaired. HBOT (1) raises pO₂ in and around the abscess, directly killing or suppressing anaerobes; (2) enhances neutrophil oxidative burst killing; (3) reduces cerebral edema via vasoconstriction; (4) promotes neovascularization of the abscess capsule, improving antibiotic penetration; and (5) may inhibit apoptosis of surrounding viable neurons.

Protocol: 2.0–2.5 ATA × 60–90 minutes, once daily for 30 sessions is the typical course. A 2025 retrospective study from Graz (PMC12307526) used 2.2 ATA × 60 minutes (one 10-minute air break) once daily, up to 30 sessions.

Outcomes: The 2025 Graz retrospective study (55 patients) found 80% complete abscess resolution in the HBOT group vs. 56% in controls at 6 months (p=0.009), with significantly better neurological outcomes at 12 months and reduced mortality. An earlier study (Bartek et al.) showed significantly better treatment response and long-term outcomes with adjuvant HBOT. The European Consensus Conference on Hyperbaric Medicine gives HBOT a Type 1, Level C recommendation for brain abscess (particularly multiple, deep, or surgically inaccessible lesions).

Evidence quality: Level C (retrospective studies, case series). Prospective RCTs lacking.

Key citations: PMC12307526 (2025 Graz retrospective study); NCBI NBK493227 (StatPearls).

10. Necrotizing Soft Tissue Infections (NSTI): Necrotizing Fasciitis and Fournier's Gangrene

What it is: NSTIs are rapidly progressive bacterial infections of the skin, subcutaneous tissue, fascia, and/or muscle with mortality rates of 20–35% even with aggressive treatment. Fournier's gangrene is the perineal and genital subset. Pathogens include group A Streptococcus, Staphylococcus aureus, mixed polymicrobial, and rarely Clostridium species. Gas in soft tissue on imaging is a hallmark. Treatment requires emergent radical surgical debridement, broad-spectrum antibiotics, and ICU support.

Why HBOT works: In NSTIs the mechanisms mirror gas gangrene: (1) bacteriostasis against anaerobic species at elevated pO₂; (2) enhanced neutrophil oxidative killing; (3) anti-inflammatory effects limiting bystander tissue damage; (4) promotion of wound healing after debridement; and (5) antibiotic potentiation (aminoglycoside uptake is oxygen-dependent).

Protocol: 2.5–3.0 ATA × 90 minutes, twice to three times daily for the first 24–48 hours, then twice daily as conditions allow. Surgical debridements occur between HBOT sessions. Total course typically 10–20 treatments.

Outcomes: A 2021 Brazilian study (PMC8103972) of 179 patients with Fournier's gangrene found mortality fell from 28.8% (no HBOT) to 3.7% (with HBOT, p<0.001). A 2022 multicenter study (PMC9356491) showed that HBOT-ineligible NSTI patients had significantly worse survival (36.4%) than those who did or did not need HBOT (~75%). A 2025 review (PMC12111948) concluded HBOT decreases mortality and morbidity in NSTI when added to standard care. A 2023 meta-analysis (PMC10040118) showed consistent reduction in mortality and complications across studies.

Evidence quality: Level C (retrospective cohort studies, no RCTs). Strong observational signal for mortality benefit.

Key citations: PMC8103972 (Fournier's gangrene mortality); PMC9356491 (multicenter NSTI); PMC12111948 (2025 NSTI review).

11. Refractory Osteomyelitis (Chronic)

What it is: Chronic refractory osteomyelitis is bone infection that persists or recurs after appropriate surgery and antibiotic therapy. It typically involves hypovascular, hypoxic bone — a consequence of the infection itself and prior treatment — that impairs leukocyte function and antibiotic penetration. Risk factors include diabetes, peripheral arterial disease, prior radiation, and implanted hardware. The infection is often polymicrobial and biofilm-forming.

Why HBOT works: (1) Directly corrects the hypoxia that disables oxidative killing by phagocytes — Mader demonstrated that tissue pO₂ in infected bone must exceed ~30 mmHg for effective leukocyte killing; (2) restores antibiotic efficacy (aminoglycosides require O₂ for bacterial membrane transport); (3) stimulates osteoclast/osteoblast activity and collagen synthesis for bone remodeling; and (4) promotes angiogenesis in avascular bone.

Protocol: 2.0–2.5 ATA × 90 minutes, once daily, 5 days/week, for 20–40 sessions total (sometimes 60+ for complex cases). One 2024 study (PubMed 38073097) used 2.5 ATA × 120 minutes, 5 days/week for ~50 days in refractory foot osteomyelitis. HBOT is always adjunctive to debridement and appropriate antibiotics.

Outcomes: The 2024 retrospective study of 80 patients with chronic foot osteomyelitis found 85% achieved total infection clearance maintained at 36-month follow-up (PubMed 38073097). Multiple smaller studies and case series document resolution or significant improvement in cases refractory to standard treatment. UHMS supports HBOT as adjunct with Level C evidence (controlled trials lacking given heterogeneity of patient populations).

Evidence quality: Level C (case series, retrospective studies). No high-quality RCTs, but consistent clinical experience over decades supports its use.

Key citations: NCBI NBK430785 (StatPearls); PubMed 38073097 (2024 foot osteomyelitis study); PMC3664446.

12. Delayed Radiation Injury (Osteoradionecrosis, Soft Tissue Radionecrosis, Hemorrhagic Cystitis, Radiation Proctitis)

What it is: Radiation damages the microvasculature of irradiated tissue, producing a progressive hypovascular-hypoxic-hypocellular fibrosis that manifests months to years post-treatment as osteoradionecrosis (ORN, particularly mandibular), soft tissue radionecrosis, hemorrhagic cystitis (after pelvic RT), and radiation proctitis. These represent ischemic wounds in an irradiated field that cannot heal through normal physiological mechanisms.

Why HBOT works: Marx's angiogenesis hypothesis: HBOT cyclically stimulates HIF-1α in hypoxic tissue borders, driving VEGF and other angiogenic signals that recruit new capillaries into the radiation-damaged zone. This creates a durable increase in tissue vascularity (demonstrated by increased tissue oxygen measurements persisting weeks after treatment ends). HBOT also mobilizes CD34+ stem/progenitor cells that differentiate into endothelial cells for new vessel formation.

Protocol: 2.0–2.5 ATA × 90 minutes, once daily, 5 days/week. Typical course: 20–30 sessions pre-operatively (for ORN with planned surgery) + 10 post-operatively ("Marx protocol" = 20 pre-op + 10 post-op). Hemorrhagic cystitis: 30–45 sessions or until hematuria resolves. Radiation proctitis: 30–40 sessions. Treatment should ideally begin within 6 months of symptom onset for hemorrhagic cystitis.

Outcomes: 2023 Cochrane review (PMC10426260, 18 studies, 1,071 participants): HBOT significantly improved outcomes for radiation proctitis (RR 1.72, p=0.04), showed significant benefit for head/neck ORN with surgery, and reduced ORN risk after dental extraction in irradiated fields. A dedicated hemorrhagic cystitis study found 86.8% complete response rate and 13.2% partial response in 38 patients treated with HBOT as primary therapy (PMC5462140). Radiation tissue injury is among the better-evidenced HBOT indications.

Evidence quality: Level A for head/neck ORN and radiation proctitis (multiple controlled trials); Level B for hemorrhagic cystitis.

Key citations: PMC10426260 (2023 Cochrane review); PMC6457778 (earlier Cochrane); PMC5462140 (hemorrhagic cystitis).

13. Compromised Skin Grafts and Flaps

What it is: Skin grafts and reconstructive flaps may fail when perfusion is marginal — from kinking, venous congestion, arterial insufficiency, radiation damage, or excessive tension. Partial graft/flap loss is common, requiring additional procedures and extended healing. The window for salvage is typically 24–72 hours after compromise is identified.

Why HBOT works: HBOT directly corrects hypoxia in the marginally perfused graft or flap, preserving cellular viability until circulation is re-established or collaterals develop. It also reduces post-ischemic edema (vasoconstriction), inhibits reperfusion injury, stimulates fibroblast activity and collagen synthesis, and accelerates angiogenesis — all of which support graft take and new vascularity.

Protocol: 2.0–2.4 ATA × 90 minutes, 2–3 times in the first 24 hours, then 1–2 times daily. HBOT should begin within 72 hours of recognized compromise; efficacy decreases substantially after 48 hours. A typical course is 20–30 sessions.

Outcomes: A 2017 review (PMC5220535) found ~90% of compromised grafts/flaps salvaged with HBOT in retrospective series. Animal studies show 29% increased skin graft survival area and significantly higher rates of complete take (>95% survival: 64% HBOT vs 17% controls). Clinical retrospective reviews report 75–90% successful salvage with HBOT initiated early. Timing is paramount: 100% graft loss was documented when HBOT started >3 days after compromise (retrospective series).

Evidence quality: Level C (retrospective clinical series, animal data; RCTs not performed). UHMS supports this indication based on consistent clinical experience.

Key citations: PMC5220535 (2017 review); NCBI NBK470219 (StatPearls); PMC11056624 (free flap case 2024).

14. Acute Thermal Burn Injury

What it is: Severe burns (>20% TBSA, deep partial thickness, or full thickness) create a necrotic central zone, a surrounding zone of stasis with impaired but recoverable perfusion, and an outer zone of hyperemia. The "zone of stasis" is at high risk of progression to necrosis from secondary ischemia, infection, and edema — potentially doubling the extent of the burn.

Why HBOT works: In burns, HBOT (1) reduces edema formation via vasoconstriction with maintained O₂ delivery; (2) inactivates neutrophil adhesion mediators, reducing progressive ischemia in the zone of stasis; (3) directly kills surface bacterial colonizers; and (4) supports fibroblast function and wound healing post-acute phase. Early HBOT is hypothesized to preserve the zone of stasis and limit burn extension.

Protocol: 2.0–2.4 ATA × 90 minutes, 3 times daily in the first 24 hours, then twice daily thereafter. A total of 30–40 sessions may be needed for large burns. Ideally initiated during initial resuscitation.

Outcomes: RCT evidence is limited and mixed. A Cochrane review (PMC8846294) identified only 2 small RCTs: Brannen (1997, n=125) showed no reduction in LOS; Hart (1974, n=16) suggested reduced fluid requirements and graft need. A 2010 review (PMC3601859) synthesized literature suggesting reduced morbidity, mortality, and hospital stay when HBOT is added to comprehensive burn care. The weight of published experience from burn centers supports HBOT for serious burns, though the RCT evidence base remains weak.

Evidence quality: Level C (two small RCTs, retrospective series). Evidence insufficient for definitive conclusions but clinical practice supports use.

Key citations: PMC8846294 (Cochrane review); PMC3601859 (practice review 2010).

15. Idiopathic Sudden Sensorineural Hearing Loss (ISSHL)

What it is: ISSHL is defined as sensorineural hearing loss of ≥30 dB across three contiguous frequencies, developing within 72 hours, with no identifiable cause. It affects ~1 in 5,000 people per year and carries ~30–50% rate of spontaneous recovery. The cochlea — particularly the stria vascularis and organ of Corti — is exquisitely sensitive to hypoxia. Hypothesized mechanisms include viral infection, vascular occlusion, autoimmunity, and endolymphatic hydrops. Oral corticosteroids are the standard of care; intratympanic dexamethasone and HBOT are adjuncts.

Why HBOT works: The cochlea has high metabolic demand, is supplied by a single end-artery (the labyrinthine artery), and has no collateral circulation. At 2.0–2.5 ATA, perilymph oxygen tension rises 3–5 fold, reversing ischemic cochlear injury and supporting hair cell recovery. HBOT enhances the anti-inflammatory effect of concurrent steroids and may reverse reversible ischemic damage before infarction becomes permanent.

Protocol: 2.0–2.5 ATA × 90 minutes once daily (or twice daily for acute cases). Treatment within 14 days of onset is recommended; the UHMS notes evidence supports benefit up to 3 months. Best evidence is for patients with moderate-to-profound loss (≥41 dB). Typically 10–20 sessions, combined with corticosteroids.

Outcomes: A 2012 Cochrane review (PMC11561530) of 7 RCTs found HBOT significantly improved the chance of ≥25% hearing recovery (RR 1.39, p=0.02) and produced a 15.6 dB greater improvement in pure-tone average (p=0.03). There was a 22% greater chance of overall improvement, with NNT=5. UHMS added this as the 14th indication in October 2011 with Class IIa, Level A designation.

Evidence quality: Class IIa, Level A (UHMS). Multiple RCTs support benefit, particularly within 14 days.

Key citations: PMC11561530 / PubMed 23076907 (Cochrane 2012); UHMS Indication 14.

16. Actinomycosis

What it is: Actinomycosis is a chronic, slowly progressive suppurative infection caused by Actinomyces israelii and related species — normal oral/GI flora that become pathogenic when introduced into tissue (trauma, dental extraction, aspiration). Cervicofacial actinomycosis is most common; abdominal, thoracic, and pelvic forms also occur. The infection forms characteristic "sulfur granules" and sinus tracts. Treatment requires prolonged antibiotic therapy (6–12 months penicillin), often with surgical debridement of fibrotic lesions.

Why HBOT works: Actinomyces species are microaerophilic to anaerobic. Elevated tissue oxygen tensions suppress growth, enhance antibiotic penetration in avascular fibrotic lesions, and restore impaired neutrophil function. HBOT is used adjunctively for deep, difficult-to-resect disease or refractory cases.

Protocol: Typically 2.0–2.5 ATA × 90 minutes, 20–30 sessions, as adjunct to long-term antibiotics. Case reports and small series guide protocol; no standardized regimen exists.

Outcomes: Evidence is limited to case reports and small series (PubMed 5394386 — original report; UHMS indication listing). Clinical experience documents favorable outcomes when HBOT is added to antibiotics in refractory or extensive actinomycosis. No controlled studies exist.

Evidence quality: Level C (case reports, physiologic rationale). Least-studied of the approved indications.

Key citations: PubMed 5394386 (Burgess and Blackstock 1971); UHMS Indication 16.

PART II: OFF-LABEL CONDITIONS

1. Traumatic Brain Injury (TBI)

Moderate-to-severe TBI from blunt trauma or blast creates primary injury (cell death) and a secondary injury cascade of edema, ischemia, neuroinflammation, and apoptosis that evolves over hours to weeks. HBOT theoretically targets the secondary cascade by correcting peri-contusional ischemia, reducing intracranial pressure (ICP) via vasoconstriction, inhibiting apoptosis, and stimulating neurogenesis.

The evidence is genuinely controversial, centering on dose and population. Dr. Paul Harch (LSU) pioneered low-pressure HBOT (1.5 ATA) for chronic mild TBI/persistent post-concussion syndrome (PPCS) in veterans, reporting significant improvements in symptoms and brain SPECT imaging. His 2012 case series of 30 veterans showed near-normalization of brain scans and elimination of suicidal ideation in the majority. However, two DoD-funded RCTs (Wolf 2012, Cifu 2011) at 1.5 and 2.4 ATA showed improvements in HBOT groups that failed to exceed sham improvements — suggesting either placebo effects or that even sham (mildly pressurized air) has therapeutic effects. A 2022 systematic review and dose analysis (PMC8968958) concluded that HBOT at exactly 1.5 ATA with 100% O₂ demonstrated statistically significant cognitive improvement in multiple RCTs for mild TBI PPCS, meeting Level 1 evidence criteria, while higher and lower doses failed.

Evidence assessment: Promising for mild TBI/PPCS at 1.5 ATA; controversial for severe acute TBI. FDA has not approved. The DoD/VA has authorized limited use for veterans with PTSD.

Key citations: PMC8968958 (2022 dose-analysis review); Harch et al., Medical Gas Research 2012.

2. Stroke (Acute and Chronic)

Acute ischemic stroke and chronic neurological deficits from past stroke both represent targets for HBOT's ability to rescue marginally perfused (penumbral) neurons or — in chronic stroke — awaken chronically dormant but structurally intact "idling neurons."

Efrati et al. (PLOS ONE 2013 — DOI 10.1371/journal.pone.0053716) conducted a prospective RCT of 74 chronic post-stroke patients (6–36 months post-injury, motor dysfunction). After 40 HBOT sessions (2 ATA × 90 min, 5 days/week × 2 months), significant improvements occurred in NIHSS, ADL, and quality of life. SPECT imaging confirmed increased perfusion in areas of SPECT/CT mismatch — live but hypometabolic cells. The cross-group design provided strong within-subject validation. For acute stroke, smaller studies suggest HBOT reduces infarct size when given within 12 hours, but no large RCT has confirmed this.

Evidence assessment: One well-designed RCT for chronic stroke (Efrati 2013). Acute stroke evidence remains early-stage. Off-label but biologically compelling.

Key citations: journals.plos.org/plosone (Efrati 2013, NCT00715897).

3. Post-Concussion Syndrome (PCS)

PCS is the persistence of concussion symptoms (headache, cognitive fog, fatigue, irritability, sleep disturbance) for months to years after mild TBI. Pathophysiology involves diffuse axonal microinjury, neuroinflammation, and impaired cerebral metabolic autoregulation. Evidence for HBOT in PPCS is best-developed among all off-label neurological indications.

A 2025 double-blind RCT (Nature Scientific Reports, PMC/nature.com) enrolled adults with persistent PCS symptoms, randomizing to 40 HBOT sessions vs. sham. From baseline to 12 months, the HBOT group showed greater improvement in neurobehavioral symptoms (NSI) and superior performance on Dynavision self-paced tasks. A 2022 systematic review (PMC8968958) found 4 RCTs at 1.5 ATA met Level 1 criteria for symptomatic and cognitive improvement. The optimal pressure window appears narrow: 1.5 ATA produces consistent benefit; higher and lower doses do not.

Evidence assessment: Multiple RCTs support benefit at 1.5 ATA. Growing toward Class I evidence for mild TBI/PPCS. Not FDA-approved.

Key citations: PMC8968958 (2022 systematic review); Nature Scientific Reports 2025.

4. Long COVID / Post-COVID Condition

Long COVID affects an estimated 10–30% of people following SARS-CoV-2 infection, presenting with fatigue, cognitive impairment ("brain fog"), dyspnea, pain, and psychiatric symptoms persisting >12 weeks. The pathophysiology involves microangiopathy, neuroinflammation, mitochondrial dysfunction, and persistent viral reservoirs. HBOT's anti-inflammatory, pro-angiogenic, and neuroplasticity-stimulating properties make it a mechanistically rational intervention.

The landmark RCT: Zilberman-Itskovich et al. (2022, phase II, n=73) demonstrated significant improvements in global cognition (p=0.038), attention, executive function, physical limitations, energy, sleep, psychiatric symptoms, and pain in the HBOT group vs. sham — corroborated by MRI-DTI showing improved brain perfusion and white matter microstructure. Hadanny et al. (2024, PubMed 38360929) followed 31 patients 1 year after HBOT completion; improvements in quality of life, sleep, pain, and psychiatric function were maintained at comparable magnitude to short-term results. Kjellberg et al. (Sweden 2023/2024) published interim safety data from a phase II RCT; the therapy was well tolerated (no serious adverse events). An Israeli registry study of cognitive and functional outcomes further supports durable benefit.

Evidence assessment: Two sham-controlled RCTs with biomarker correlation. Evidence quality is strengthening rapidly. Likely to become the most important off-label indication given disease burden.

Key citations: PMC11051078 (systematic review with trial table); PubMed 38360929 (Hadanny 2024 long-term follow-up); Zilberman-Itskovich et al. 2022.

5. Post-Traumatic Stress Disorder (PTSD)

PTSD involves dysregulation of the amygdala-prefrontal circuits, impaired hippocampal neurogenesis, and chronic neuroinflammation. HBOT first appeared relevant to PTSD as a serendipitous finding during veteran TBI treatment; PTSD symptoms improved alongside TBI symptoms. Mechanistically, HBOT promotes hippocampal neurogenesis (animal data), reduces neuroinflammation, and improves prefrontal cortex function.

A 2024 systematic review (PMC11179433) identified 10 clinical trials (6 controlled) for HBOT in PTSD. Multiple studies showed significant PCL score reductions after HBOT. A controlled trial by Hadanny et al. in veterans found significant improvement in CAPS-5 PTSD scores post-HBOT with no change in controls. Harch's 2012 veteran case series and the DoD-sponsored Wolf (2012) and Cifu studies document consistent PTSD symptom improvement — with PTSD patients actually showing greater improvement than non-PTSD patients in some analyses. The DoD and VA have authorized limited HBOT use for veterans with combat-related PTSD and TBI.

Evidence assessment: 10 trials (6 controlled); promising but not definitive. Controversy remains around sham design — pressurized air at 1.3 ATA may itself have therapeutic effects on PTSD neurobiologically.

Key citations: PMC10630921 (PMC use in veterans); PMC11179433 (2024 systematic review).

6. Fibromyalgia

Fibromyalgia syndrome (FMS) is characterized by widespread chronic pain, fatigue, and cognitive impairment. Neuroimaging demonstrates abnormal brain activity — hyperactivity in pain processing regions (posterior cortex) and hypoactivity in frontal inhibitory areas.

Efrati et al. (PLOS ONE 2015, DOI 10.1371/journal.pone.0127012) conducted a crossover RCT in 60 women with FMS. After 40 HBOT sessions (2 ATA × 90 min), all FMS symptoms significantly improved in both groups; SPECT imaging confirmed normalization of abnormal brain activity. Effect sizes were large. A 2023 RCT (PLOS ONE, PMC11179433 companion) compared HBOT to pharmacotherapy (pregabalin or duloxetine) in 60 FMS patients with TBI history; HBOT produced significantly greater pain reduction (d = −0.95, p=0.001) and quality-of-life improvement with corroborating SPECT findings.

Evidence assessment: Two RCTs with biomarker correlation suggest genuine effect. Mechanism is neuroplasticity-based, not primarily angiogenic. Evidence quality is moderate.

Key citations: PLOS ONE 2015 (Efrati — DOI 10.1371/journal.pone.0127012); PLOS ONE 2023 (HBOT vs. pharmacotherapy — DOI 10.1371/journal.pone.0282406).

7. Lyme Disease / Post-Treatment Lyme Disease Syndrome (PTLDS)

Lyme disease from Borrelia burgdorferi infection is treated with antibiotics, but ~10–20% of patients develop persistent symptoms (fatigue, cognitive difficulties, pain) — PTLDS. The pathophysiology remains debated (autoimmunity vs. persistent infection vs. neuroinflammation). HBOT was proposed in the 1990s on the premise that Borrelia species might be microaerophilic and that HBOT could reduce neuroinflammation.

The evidence is extremely limited. A 1998 case series (Fife et al.) reported improvement in some PTLDS patients. A 2014 case report (PubMed 24726678) documented successful HBOT adjuvant therapy in chronic Lyme. There are no RCTs. Notably, a Dartmouth case report described Lyme disease developing DURING HBOT, casting doubt on a prophylactic effect. HBOT is not recommended by IDSA or major infectious disease societies for PTLDS.

Evidence assessment: Very limited (case reports only). No controlled evidence. Use is speculative and not evidence-based. High risk of harm through delayed appropriate care.

Key citations: PubMed 24726678 (case report 2014).

8. Multiple Sclerosis

HBOT for MS peaked in the 1980s following Fischer et al.'s 1983 NEJM publication showing improvement in 12/17 MS patients at 2 ATA. By 1984, Neubauer had treated >10,000 patients in 14 countries, reporting 70% improvement rates. However, a 2010 systematic review and meta-analysis (PMC6493844) of 12 RCTs (all conducted 1983–1987) found no clinically significant benefit on MS disability progression. The trials used 1.75–2.5 ATA × 60–120 minutes × 20 sessions.

Current evidence does not support HBOT for MS progression. Some advocates suggest that higher-quality long-term "top-up" protocols may be beneficial (consistent with Neubauer's theory of maintaining vascular oxygen gradients), but this has not been tested in modern RCTs.

Evidence assessment: Negative meta-analysis of 12 RCTs. Not recommended. Historical interest only.

Key citations: PMC6493844 (2010 systematic review and meta-analysis).

9. Cerebral Palsy

HBOT for CP is driven by the concept that periventricular white matter hypoxia in the injured brain is reversible. The McGill RCT (Collet et al., Lancet 2001) enrolled 111 children with CP and found similar improvements in the HBOT group (1.75 ATA × 100% O₂) AND the sham group (1.3 ATA pressurized air) — suggesting both the pressure effect and parental attention/expectation confounded results. A 2022 systematic review (PMC9565562 / PLOS ONE) of 5 RCTs (4 high-quality) found high-level evidence that HBOT does NOT improve motor function, cognition, or functional performance in children with CP compared to controls. Middle ear barotrauma occurs in up to 50% of treated children.

Evidence assessment: High-level evidence of ineffectiveness. Not recommended. The apparent improvement in the McGill sham arm remains controversial (whether pressurized air at 1.3 ATA itself has biological effects).

Key citations: PMC9565562 (2022 systematic review); Collet et al. Lancet 2001; canchild.ca review.

10. Autism Spectrum Disorder (ASD)

The rationale for HBOT in ASD centers on evidence of cerebral hypoperfusion (SPECT studies), neuroinflammation, and oxidative stress in some ASD children. Rossignol et al. conducted the first RCT (Rossignol et al. 2009, BMC Pediatrics): 62 children randomized to 40 sessions at either 1.3 ATA/24% O₂ or 1.03 ATA/21% O₂. The HBOT group showed significant improvements in overall functioning, receptive language, eye contact, and behavior (p<0.05 for multiple CGI domains). A subsequent pilot RCT (Bent et al.) found no cytokine changes and mixed behavioral results. A Cochrane review (PMC6464144) of 5 RCTs concluded insufficient evidence to recommend HBOT for ASD.

Evidence assessment: Mixed RCT evidence; Rossignol RCT positive but small and used low pressure. Cochrane: insufficient evidence. Not recommended outside trials.

Key citations: PMC5471082 (review of ASD studies); PMC6464144 (Cochrane 2016); Rossignol 2009 (BMC Pediatrics).

11. Crohn's Disease (Perianal Fistulizing)

Crohn's disease with perianal fistulas is notoriously refractory to medical and surgical treatment. HBOT reduces intestinal inflammation via oxidative pathway modulation and may promote healing of hypovascular fistula tracts. The HOT-TOPIC trial (PMC8911540, n=20) — the largest prospective study — used 40 daily sessions (2.4 ATA × 90 min with air breaks). At 16 weeks, both the PDAI and modified Van Assche MRI index improved significantly. At 60-week follow-up, clinical and radiologic improvements were maintained, with 20% achieving deep fibrotic healing on MRI and 60% having inactive perianal disease. A 2024 registry study (PubMed 37682003) confirmed safety and promising efficacy.

Evidence assessment: Single prospective cohort (no RCT) with 1-year follow-up. Promising for refractory perianal CD fistulas. Needs confirmatory RCT.

Key citations: PMC8911540 (HOT-TOPIC trial 1-year follow-up); PubMed 37682003 (registry 2024).

12. Migraines and Cluster Headaches

A 2015 Cochrane review (PMC8720466) of 11 trials found low-quality evidence that HBOT significantly terminated acute migraine attacks vs. sham (RR 6.21, 95% CI 2.41–16.00; three trials, 58 participants). Normobaric oxygen (NBO) showed similar benefit for cluster headaches — consistent with oxygen's established ability to abort cluster attacks via vasoconstriction of distal cerebral resistance vessels. There was no evidence for either HBOT or NBO preventing future attacks. Given the cost and availability limitations of HBOT, it is not a practical first-line option; standard abortive medications are preferred.

Evidence assessment: Low-quality evidence of acute attack termination. Not cost-effective for routine use. NBO (cheap and accessible) is more practical for cluster headaches.

Key citations: PMC8720466 (Cochrane 2015).

13. Alzheimer's Disease and Cognitive Aging

Alzheimer's pathology involves amyloid plaques, tau neurofibrillary tangles, and critically — cerebral microvascular dysfunction with reduced cerebral blood flow (CBF). Shapira et al. (Aging 2021, aging-us.com/article/203485) treated 5XFAD AD mice with HBOT and demonstrated: increased CBF, reduced amyloid plaque volume (including pre-existing plaques — first demonstration in vivo), and improved cognition. In a human pilot (n=6, age 70±2.7 years with significant memory loss), 60 HBOT sessions increased global cognitive score significantly (102.4 → 109.5, p=0.004) with CBF improvements on SPECT. Hadanny et al. have produced additional human studies showing HBOT improves cognitive scores in mild cognitive impairment (MCI).

Evidence assessment: Compelling animal data; small human pilots with positive signals. No large RCT. A pivotal trial is ongoing. Evidence currently insufficient for clinical recommendation outside research settings.

Key citations: aging-us.com Shapira 2021 (PMC equivalent); Frontiers Aging 2021.

14. Avascular Necrosis (Osteonecrosis of the Femoral Head)

AVN (ONFH) results from disrupted blood supply to the femoral head, causing bone infarction and potential collapse. Risk factors include corticosteroids, alcohol, sickle cell disease, trauma, and diving. HBOT promotes angiogenesis and reduces ischemia in the necrotic zone, potentially halting progression before femoral head collapse.

A 2021 meta-analysis (PMC7999152) of multiple studies found significant clinical improvement in patients with ONFH treated with HBOT — particularly for early-stage (Ficat I–II) disease before collapse. A 2025 meta-analysis (PMC12232396) found significant VAS pain score reduction (MD −2.94, p<0.0001) and SF-12 improvements, but no significant difference vs. non-HBOT controls in several outcomes, reflecting heterogeneous study quality. Italy includes ONFH as a reimbursed HBOT indication (protocol: 2.2–2.5 ATA × 60–90 min × 60–90 sessions). The European Consensus on Hyperbaric Medicine endorses HBOT for early ONFH.

Evidence assessment: Moderate evidence, particularly for early-stage disease. Lacks large RCTs. European consensus supports use for Ficat I–III.

Key citations: PMC7999152 (2021 meta-analysis); PMC12232396 (2025 updated meta-analysis).

15. Sports and Athletic Recovery

HBOT has been promoted for accelerating recovery from exercise-induced muscle damage (EIMD) and sports injuries. Proposed mechanisms include reducing inflammatory cytokines, accelerating lactate clearance, and promoting satellite cell activation for muscle repair.

A 2024 RCT in elite youth football players (Frontiers in Physiology) found a single HBOT session after a match did not significantly improve biochemical recovery markers or performance vs. control — though the HBOT group reported lower perceived fatigue (Hooper Index). A PMC review (PMC3382683) found athletes treated with HBOT showed faster recovery rates in earlier studies with lactic acid and ammonia clearance. Evidence is inconsistent and most studies are small.

Evidence assessment: Insufficient evidence for routine athletic use. Single sessions appear ineffective. Multiple sessions post-injury may have some benefit (consistent with FDA-approved injury indications). The wellness/performance market for HBOT outpaces evidence.

Key citations: PMC3382683 (sports injuries review); Frontiers Physiology 2024 (football RCT).

16. Anti-Aging / Telomere Length

Hadanny and Efrati (Aging 2020, PMC7746357/PubMed 33206062) studied 35 healthy adults aged ≥64 who received 60 daily HBOT sessions without lifestyle changes. Peripheral blood mononuclear cell (PBMC) telomere lengths increased by >20% for T helper, T cytotoxic, NK, and B cells, with B cells showing the largest increase (37.6% post-HBOT, p=0.007). Senescent T-helper cells decreased by 37.3% (p<0.0001). The authors described this as the first human demonstration of telomere elongation and senescent cell clearance through HBOT.

These findings require important caveats: (1) PBMC telomere length is an imperfect surrogate for organismal aging; (2) there is no evidence of clinical longevity benefit; (3) the study had no sham control; and (4) it is unclear whether intermittent hyperoxia-induced signaling (similar to ischemic preconditioning) is the mechanism or whether repeated sessions would be needed indefinitely.

Evidence assessment: Interesting pilot data, no RCT, no clinical longevity endpoints. Mechanism biologically plausible. Currently insufficient for clinical anti-aging use.

Key citations: PMC7746357 (Hadanny et al. 2020, Aging).

17. Plastic Surgery Recovery (Post-Facelift, Post-Rhinoplasty)

HBOT has entered concierge plastic surgery practices to reduce bruising, swelling, and downtime after cosmetic procedures. The proposed mechanism is HBOT's established ability to reduce ischemia-reperfusion injury, edema, and inflammatory cell adhesion — similar to mechanisms supporting compromised flap salvage (an FDA-approved indication).

A 2023 retrospective study (PMC10387739) assessed HBOT in postoperative aesthetic surgery patients. HBOT groups showed faster resolution of edema and bruising and reduced inflammatory markers. A 2025 case series in hair transplant patients (PMC12812318) showed accelerated epithelialization and resolution of crusting. The FDA-approved compromised flap indication provides a biologic and regulatory bridge to cosmetic recovery use.

Evidence assessment: Limited retrospective evidence. Compelling theoretical basis given the FDA-approved skin graft/flap indication. No RCTs. Growing clinical adoption despite limited formal evidence.

Key citations: PMC10387739 (2023 aesthetic surgery retrospective); PMC12812318 (hair transplant 2025).

18. Erectile Dysfunction (Vasculogenic)

Vasculogenic ED involves progressive endothelial dysfunction and penile microangiopathy — a penile expression of systemic cardiovascular disease. Hadanny et al. (Nature/International Journal of Impotence Research, 2018 — PubMed 29773856) treated 30 men with chronic ED unresponsive to PDE5 inhibitors with 40 HBOT sessions. IIEF erectile function domain improved 88% (p<0.0001); 80% reported global treatment success. Perfusion MRI demonstrated 153% increase in K-trans (capillary permeability × blood flow) in corpus cavernosum. A 2023 meta-analysis (PubMed 37952207) found a significant MD of 10.50 for pure vasculogenic ED studies, though heterogeneity was high.

Evidence assessment: Prospective pilot study (n=30) with compelling perfusion MRI data. Mechanism (penile angiogenesis) is biologically sound. Needs larger RCT. Currently off-label but mechanistically rational.

Key citations: PubMed 29773856 (Hadanny 2018); PubMed 37952207 (2023 meta-analysis).

19. Bell's Palsy

Bell's palsy is idiopathic facial nerve palsy, likely viral (HSV-1 reactivation) in most cases, causing unilateral facial muscle paralysis. Standard treatment is oral corticosteroids ± antivirals. HBOT is proposed to reduce inflammation and edema compressing the facial nerve within the fallopian canal, enhance nerve perfusion, and promote neuroregenerative signaling.

A case series (PMC12088541, 2025, n=7) found significant improvements in facial function in all patients receiving HBOT + standard treatment, with faster recovery than historical controls. An earlier RCT comparison (PMC8406519, n=91) found 95% recovery with HBOT vs. 76% with steroids alone (RR 1.26, 95% CI 1.04–1.53). A 2025 case report (JPMS) described complete recovery using 2.5 ATA × 80 minutes × 18 sessions.

Evidence assessment: Small RCT and case series data suggest benefit as adjunct to steroids. Not standard of care. Reasonably supported for moderate-to-severe palsy.

Key citations: PMC12088541 (2025 case series); PMC8406519 (RCT comparison).

20. Pyoderma Gangrenosum (PG)

PG is a severe, painful neutrophilic dermatosis causing rapidly progressing ulceration, often associated with IBD, rheumatoid arthritis, or hematologic malignancy. It is notoriously difficult to treat. HBOT has been used adjunctively in PG refractory to standard immunosuppressive therapy.

Evidence consists exclusively of case reports and small series. A Slovenian review (acta-apa.mf.uni-lj.si/2019) discusses HBOT in PG alongside other dermatologic conditions, noting positive outcomes in case reports. Sciencedirect 2024 published a case of challenging PG healing with adjunctive HBOT. The anti-neutrophilic, anti-inflammatory, and wound-healing-promoting properties of HBOT provide theoretical rationale.

Evidence assessment: Case reports only. No controlled evidence. Potentially useful in refractory PG as salvage adjunct.

21. Inflammatory Bowel Disease (General)

Beyond perianal Crohn's fistulas (covered above), HBOT has been explored for active luminal IBD (Crohn's disease and ulcerative colitis). The gut mucosa is highly oxygen-sensitive; active IBD creates mucosal hypoxia that perpetuates inflammation. HBOT may break this cycle by correcting hypoxia and reducing pro-inflammatory cytokine production.

Case series and small studies report remission in IBD flares treated with HBOT. The UHMS 2020 conference abstracts (UHMS 2020 session) describe a Crohn's perianal fistula HBOT study. Evidence remains case-report level for luminal IBD specifically.

Evidence assessment: Very limited; mostly case reports for luminal IBD. Stronger evidence specific to perianal CD fistulas (see Crohn's entry).

22. Sickle Cell Crisis (Vaso-Occlusive Crisis)

In sickle cell disease (SCD), deoxygenated HbS polymerizes, causing red cell sickling, vaso-occlusion, pain crises, and acute chest syndrome. HBOT theoretically reverses hypoxia-driven sickling, improves microvascular flow, and breaks the vaso-occlusion cycle.

A JAMA case report (1976) described successful resolution of sickle cell crisis with HBOT. A 2024 multicentric RCT protocol (PMC11605825) is underway — a triple-blind superiority RCT comparing HBOT to sham for vaso-occlusive crisis. There is a ClinicalTrials.gov entry (NCT03412045). Current evidence is at case report/early trial stage.

Evidence assessment: Biologically rational; currently under investigation in RCT. No completed controlled trial. Experimental.

Key citations: JAMA 1976 (Painful SCD crisis); PMC11605825 (RCT protocol 2024).

23. Macular Degeneration (Age-Related)

The macula's high metabolic demand and dependence on choroidal circulation makes it susceptible to hypoxia-driven degeneration. HBOT could theoretically supplement oxygen delivery to the outer retina. A small Yugoslav study (Bojic et al.) found visual acuity doubled in 3/4 AMD patients after HBOT. No subsequent controlled trials have been performed.

Evidence assessment: Extremely limited (one small series). Not recommended outside research settings. HBOT for AMD remains experimental.

24. Diabetic Retinopathy

Diabetic retinopathy involves retinal microangiopathy and neovascularization driven by hypoxia-induced VEGF upregulation. Paradoxically, HBOT's pro-angiogenic properties (beneficial elsewhere) might worsen neovascular proliferative retinopathy; conversely, correcting retinal hypoxia might suppress ischemic VEGF drive and slow non-proliferative disease.

Evidence is very limited — primarily laboratory data and case reports. Clinical use for diabetic retinopathy is not established.

Evidence assessment: Theoretical basis; insufficient human evidence. Not recommended clinically outside trials.

25. Tinnitus (Idiopathic)

Tinnitus often co-occurs with ISSHL, and the cochlear hypoxia rationale from ISSHL applies. For ISSHL-associated tinnitus, HBOT data from ISSHL RCTs suggest concurrent benefit. For idiopathic tinnitus without hearing loss, evidence is weaker. The 2012 Cochrane ISSHL review noted one trial (Fattori 2001) showed 61% vs. 24% improvement in hearing when treated with HBOT — tinnitus was not separately analyzed. For pure tinnitus, there is no strong independent evidence base.

Evidence assessment: Possibly beneficial when associated with ISSHL; insufficient evidence for isolated tinnitus. Often treated at centers using the ISSHL protocol.

26. Frostbite

Frostbite causes microvascular thrombosis, ice crystal cell injury, and progressive ischemia-reperfusion injury during rewarming. HBOT is proposed to reduce reperfusion injury, inhibit leukocyte-endothelial adhesion, and promote microvascular recovery.

Evidence consists primarily of case reports and case series. A 2011 PMC report (PMC4596071) described complete recovery without epiphyseal injury in an 11-year-old with third-degree frostbite after 20 HBOT sessions. StatPearls (NBK448115) acknowledges HBOT as an adjunctive option. Current frostbite clinical guidelines (frostbitecare.ca) note tPA and iloprost have stronger evidence; HBOT is an adjunct in severe cases.

Evidence assessment: Case report level. Biologically rational. Not yet supported by controlled trials.

Key citations: PMC4596071 (pediatric frostbite case); NBK448115 (StatPearls).

27. Hidradenitis Suppurativa (HS)

HS is a chronic neutrophilic inflammatory skin disease causing painful nodules, abscesses, and sinus tracts in apocrine gland-bearing areas (axillae, groin, perianal). The anaerobic bacterial component of HS microbiome and the chronically hypoxic wound environment provide rationale for HBOT. A 2019 Slovenian review (acta-apa.mf.uni-lj.si/2019) discusses HBOT in HS with positive case-series outcomes alongside PG. No RCTs have been published.

Evidence assessment: Case reports and small series only. Mechanistically rational given the FDA-approved NSTI indication in related skin conditions.

28. Stem Cell Mobilization (Wellness)

Stem and Bhutiani (PNAS 2006, PubMed 16299259) demonstrated that a single HBOT session at 2.0 ATA doubled circulating CD34+ stem/progenitor cells in humans. Over 20 sessions, circulating CD34+ cells increased 8-fold via a nitric oxide–dependent mechanism. A follow-up study (PMC4037447) confirmed CD34+/CD45-dim cell mobilization with 2.5 ATA > 2.0 ATA protocols, with mobilized cells showing higher concentrations of HIF-1α and other regulatory proteins.

This stem cell mobilization is the mechanism underlying HBOT's angiogenic and tissue-regenerative effects across multiple FDA-approved indications. It has been adopted by the wellness industry as a justification for repeated HBOT sessions in ostensibly healthy individuals seeking "regenerative" benefits. Whether stem cell mobilization in a healthy individual produces clinical benefit beyond what endogenous turnover provides remains unproven.

Evidence assessment: The mobilization biology is well-established. Clinical benefit from stem cell mobilization in healthy people is unproven. The mechanism is real; the wellness application is speculative.

Key citations: PubMed 16299259 (Thom et al. 2006, PNAS); PMC4037447.

29. Hair Transplant Recovery

Post-follicular unit transplantation (FUT/FUE) complications include graft shedding, folliculitis, and prolonged crusting. HBOT's wound-healing and anti-inflammatory properties have been applied to accelerate recovery.

A 2021 RCT (PubMed 32770782, n=~60) found HBOT significantly reduced post-surgical follicle shedding (27.6% vs 69.1% in controls), reduced folliculitis and itching, though 9-month graft survival was similar between groups (96.9% vs 93.8%). A 2025 case series (PMC12812318) documented accelerated epithelialization and earlier resolution of crusting with HBOT in the immediate post-operative period.

Evidence assessment: One small RCT showing reduced shedding and inflammation but similar long-term survival. HBOT appears useful for reducing early recovery symptoms. Needs larger confirmatory RCT.

Key citations: PubMed 32770782 (2021 RCT); PMC12812318 (2025 case series).

30. Pediatric Anoxic Brain Injury / Near-Drowning

Anoxic brain injury from near-drowning or cardiac arrest creates massive neuronal injury from global ischemia, followed by a secondary injury phase of reperfusion injury, glutamate excitotoxicity, and cerebral edema. HBOT targets this secondary phase.

Harch et al. (PMC5510296, 2017) described a remarkable case: a 2-year-old girl who spent 5–15 minutes underwater developed severe neurological deficits and MRI-documented cerebral cortical and white matter atrophy. She began normobaric oxygen therapy at day 56, then HBOT at 1.3 ATA × 45 minutes from day 79. After 39 HBOT sessions, she recovered near-normal speech, cognition, and gait. Sequential MRI showed near-complete reversal of cortical and white matter atrophy. This case generated significant attention and was widely discussed.

Evidence assessment: Single compelling case report (Harch 2017). Several similar case reports exist. No RCTs. The case is extraordinary and biologically plausible but cannot be generalized without controlled data. Children may have greater neuroplasticity than adults.

Key citations: PMC5510296 (Harch 2017 near-drowning case).

Evidence Quality Summary

All citations are drawn from peer-reviewed publications available on PubMed (NCBI), PLOS ONE, Nature journals, Frontiers, and the Undersea and Hyperbaric Medical Society (UHMS) evidence compendium.